See more : Hamilton Lane Alliance Holdings I, Inc. (HLAHW) Income Statement Analysis – Financial Results
Complete financial analysis of Hypera S.A. (HYPE3.SA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hypera S.A., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Capstone Companies, Inc. (CAPC) Income Statement Analysis – Financial Results
- CITIC Telecom International Holdings Limited (1883.HK) Income Statement Analysis – Financial Results
- Autoneum Holding AG (0QOB.L) Income Statement Analysis – Financial Results
- OceanTech Acquisitions I Corp. (OTEC) Income Statement Analysis – Financial Results
- Redefine Properties Limited (RDF.JO) Income Statement Analysis – Financial Results
Hypera S.A. (HYPE3.SA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hyperapharma.com.br
About Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.91B | 7.55B | 5.94B | 4.09B | 3.29B | 3.72B | 3.64B | 3.29B | 2.96B | 4.68B | 4.26B | 3.87B | 3.32B | 3.16B | 2.03B | 1.33B | 1.06B | 380.27M | 346.70M |
| Cost of Revenue | 2.92B | 2.78B | 2.13B | 1.46B | 1.21B | 1.06B | 926.75M | 846.79M | 746.51M | 1.70B | 1.51B | 1.46B | 1.32B | 1.35B | 842.94M | 534.94M | 446.90M | 187.81M | 131.80M |
| Gross Profit | 5.00B | 4.76B | 3.80B | 2.63B | 2.09B | 2.67B | 2.71B | 2.44B | 2.21B | 2.98B | 2.75B | 2.41B | 2.00B | 1.81B | 1.18B | 798.06M | 614.60M | 192.46M | 214.90M |
| Gross Profit Ratio | 63.12% | 63.10% | 64.05% | 64.30% | 63.30% | 71.56% | 74.53% | 74.25% | 74.75% | 63.71% | 64.55% | 62.19% | 60.28% | 57.17% | 58.38% | 59.87% | 57.90% | 50.61% | 61.98% |
| Research & Development | 169.51M | 159.39M | 126.69M | 151.65M | 128.72M | 73.92M | 0.00 | 73.29M | 11.30M | 16.16M | 13.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 84.36M | 92.81M | 67.42M | 48.19M | 42.79M | 49.81M | 172.42M | 145.69M | 149.96M | 225.85M | 207.47M | 81.12M | 259.86M | 196.01M | 128.07M | 72.52M | 62.40M | 38.12M | 19.00M |
| Selling & Marketing | 1.69B | 1.76B | 1.48B | 1.16B | 1.23B | 1.20B | 1.26B | 1.18B | 1.10B | 1.67B | 1.52B | 1.02B | 1.28B | 1.07B | 663.70M | 437.36M | 325.50M | 118.51M | 146.90M |
| SG&A | 1.78B | 1.85B | 1.55B | 1.21B | 1.27B | 1.25B | 1.44B | 1.32B | 1.25B | 1.89B | 1.73B | 1.10B | 1.54B | 1.27B | 791.77M | 509.88M | 387.90M | 156.63M | 165.90M |
| Other Expenses | 3.05B | 289.92M | 175.56M | -17.39M | 246.04M | 61.36M | 11.29M | -26.91M | 1.63M | -55.03M | 143.50M | -52.33M | 40.15M | -70.56M | -73.97M | -332.69M | 400.00K | 19.00K | -5.80M |
| Operating Expenses | 5.00B | 2.30B | 1.85B | 1.34B | 1.65B | 1.50B | 1.57B | 1.38B | 1.31B | 1.95B | 1.87B | 1.51B | 1.58B | 1.19B | 717.80M | 517.30M | 639.50M | 169.74M | 174.20M |
| Cost & Expenses | 5.44B | 5.09B | 3.99B | 2.80B | 2.85B | 2.56B | 2.49B | 2.23B | 2.06B | 3.65B | 3.38B | 2.98B | 2.90B | 2.55B | 1.56B | 1.05B | 1.09B | 357.55M | 306.00M |
| Interest Income | 180.64M | 70.85M | 35.93M | 26.88M | 30.84M | 21.91M | 28.84M | 32.81M | 199.16M | 179.76M | 157.37M | 205.18M | 268.08M | 147.26M | 50.18M | 48.31M | 5.13M | 1.33M | 2.31M |
| Interest Expense | 1.35B | 986.08M | 383.22M | 176.09M | 43.22M | 46.24M | 67.45M | 228.30M | 517.50M | 434.07M | 377.26M | 409.98M | 876.51M | 330.49M | 35.60M | 318.46M | 77.40M | 22.65M | 9.31M |
| Depreciation & Amortization | 238.31M | 167.15M | 132.07M | 117.42M | 116.17M | 85.00M | 68.08M | 63.94M | 106.98M | 109.53M | 104.91M | 97.68M | 113.46M | 49.30M | 38.51M | 32.43M | 253.30M | 16.34M | 7.80M |
| EBITDA | 2.88B | 2.80B | 2.18B | 1.55B | 1.26B | 1.36B | 1.35B | 1.14B | 992.48M | 948.98M | 1.11B | 869.60M | 491.19M | 765.15M | 525.49M | 67.71M | 228.40M | 42.35M | 48.50M |
| EBITDA Ratio | 36.35% | 37.26% | 36.55% | 37.17% | 38.53% | 36.85% | 37.64% | 36.93% | 38.37% | 26.01% | 26.00% | 28.71% | 24.14% | 25.59% | 27.32% | 23.49% | 21.52% | 10.50% | 13.99% |
| Operating Income | 2.50B | 2.64B | 2.04B | 1.40B | 1.09B | 1.23B | 1.16B | 1.07B | 883.86M | 910.09M | 896.56M | 770.59M | 421.01M | 611.96M | 464.53M | 280.76M | 49.10M | -5.87M | 33.60M |
| Operating Income Ratio | 31.56% | 35.02% | 34.30% | 34.20% | 32.95% | 33.02% | 31.88% | 32.50% | 29.89% | 19.44% | 21.05% | 19.89% | 12.66% | 19.37% | 22.94% | 21.06% | 4.63% | -1.54% | 9.69% |
| Total Other Income/Expenses | -988.44M | -1.03B | -391.96M | -154.92M | 14.42M | 85.00K | 53.35M | -192.13M | -523.43M | -411.28M | -618.04M | -425.39M | -608.43M | -183.23M | 46.91M | -602.85M | 400.00K | -24.41M | -12.62M |
| Income Before Tax | 1.51B | 1.61B | 1.64B | 1.24B | 1.10B | 1.23B | 1.21B | 876.85M | 368.00M | 493.32M | 313.90M | 345.71M | -187.42M | 428.73M | 479.12M | -322.09M | 49.50M | -5.85M | 27.80M |
| Income Before Tax Ratio | 19.07% | 21.35% | 27.69% | 30.41% | 33.39% | 33.02% | 33.35% | 26.66% | 12.45% | 10.54% | 7.37% | 8.92% | -5.64% | 13.57% | 23.66% | -24.16% | 4.66% | -1.54% | 8.02% |
| Income Tax Expense | -141.64M | -95.35M | 26.58M | -78.17M | -88.89M | 94.46M | 101.87M | 202.38M | 22.51M | 81.12M | 55.08M | 117.65M | -14.60M | 166.83M | 165.74M | 758.79M | 8.50M | -2.91M | -3.20M |
| Net Income | 1.65B | 1.70B | 1.33B | 1.30B | 1.16B | 1.13B | 964.94M | 1.17B | 559.87M | 402.70M | 256.72M | 203.91M | -54.65M | 261.90M | 313.37M | -207.88M | 42.10M | -2.93M | 31.00M |
| Net Income Ratio | 20.82% | 22.48% | 22.40% | 31.67% | 35.33% | 30.33% | 26.52% | 35.71% | 18.94% | 8.60% | 6.03% | 5.26% | -1.64% | 8.29% | 15.47% | -15.59% | 3.97% | -0.77% | 8.94% |
| EPS | 2.61 | 2.68 | 2.10 | 2.05 | 1.84 | 1.79 | 1.53 | 1.87 | 0.89 | 0.64 | 0.41 | 0.33 | -0.09 | 0.50 | 0.70 | -0.52 | 0.13 | -0.01 | 0.10 |
| EPS Diluted | 2.58 | 2.65 | 2.08 | 2.03 | 1.82 | 1.77 | 1.52 | 1.84 | 0.87 | 0.63 | 0.40 | 0.33 | -0.08 | 0.49 | 0.67 | -0.52 | 0.13 | -0.01 | 0.10 |
| Weighted Avg Shares Out | 632.46M | 632.21M | 631.97M | 631.39M | 631.29M | 632.00M | 630.51M | 631.48M | 632.16M | 631.68M | 629.43M | 625.63M | 620.82M | 528.17M | 419.99M | 397.20M | 317.32M | 317.32M | 317.32M |
| Weighted Avg Shares Out (Dil) | 637.79M | 639.10M | 639.53M | 638.34M | 639.94M | 639.50M | 636.41M | 641.51M | 643.80M | 644.10M | 645.28M | 671.18M | 668.12M | 561.11M | 433.39M | 397.20M | 317.32M | 317.32M | 317.32M |
Source: https://incomestatements.info
Category: Stock Reports